Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Pharmalot: Report Finds Prescription Medicine Prices Rose in 2014

New York, NY, January 27, 2015 ― Pharmalot reports that the prices of prescription medicines is a front-and-center issue as the cost to treat everything from some of the rarest diseases to the most common afflictions is causing increasing concern among payers, physicians and consumers.

But how much exactly did prices rise last year?

A new analysis indicates prices rose significantly across the board for all types of medicines.  

Overall, prices for brand, generic and specialty drugs combined increased 10.9% in 2014 from the year before, according to Truveris, a research firm that tracks drug pricing.  The firm analyzed more than 300 million payments to U.S. pharmacies for prescriptions and developed an index based on price and utilization.

Breaking it down by category, prices for brand-name drug rose 14.8%, specialty drug prices increased 9.7% and generic medicines climbed 4.9%.

Pharmalot, a Wall Street Journal blog and a rich source of biopharma sector news, explores the fast-moving, complicated world that develops and markets medicines — and the drug makers that are attempting to replenish their pipelines while grappling with pricing and regulatory dictates, among many other challenges.

For the full Pharmalot story, click here.

You may also follow Pharmalot on Twitter at @Pharmalot.